362 related articles for article (PubMed ID: 37901257)
1. Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.
Blanchard R; Adjei I
RSC Adv; 2023 Oct; 13(45):31411-31425. PubMed ID: 37901257
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
3. Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy.
Kudruk S; Forsyth CM; Dion MZ; Hedlund Orbeck JK; Luo J; Klein RS; Kim AH; Heimberger AB; Mirkin CA; Stegh AH; Artzi N
Proc Natl Acad Sci U S A; 2024 Feb; 121(8):e2306973121. PubMed ID: 38346200
[TBL] [Abstract][Full Text] [Related]
4. Biophysical Control of the Glioblastoma Immunosuppressive Microenvironment: Opportunities for Immunotherapy.
Teer L; Yaddanapudi K; Chen J
Bioengineering (Basel); 2024 Jan; 11(1):. PubMed ID: 38247970
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based immunotherapy of pancreatic cancer.
Noubissi Nzeteu GA; Gibbs BF; Kotnik N; Troja A; Bockhorn M; Meyer NH
Front Mol Biosci; 2022; 9():948898. PubMed ID: 36106025
[TBL] [Abstract][Full Text] [Related]
6. Managing the TME to improve the efficacy of cancer therapy.
Bilotta MT; Antignani A; Fitzgerald DJ
Front Immunol; 2022; 13():954992. PubMed ID: 36341428
[TBL] [Abstract][Full Text] [Related]
7. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
8. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
[TBL] [Abstract][Full Text] [Related]
9. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
10. Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
Giles B; Nakhjavani M; Wiesa A; Knight T; Shigdar S; Samarasinghe RM
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686652
[TBL] [Abstract][Full Text] [Related]
11. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
12. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
[TBL] [Abstract][Full Text] [Related]
13. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.
Xu Y; Xiong J; Sun X; Gao H
Acta Pharm Sin B; 2022 Dec; 12(12):4327-4347. PubMed ID: 36561994
[TBL] [Abstract][Full Text] [Related]
14. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
15. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.
Melo V; Bremer E; Martin JD
Front Cell Dev Biol; 2022; 10():908389. PubMed ID: 35712656
[TBL] [Abstract][Full Text] [Related]
16. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
[TBL] [Abstract][Full Text] [Related]
18. Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy.
Park JH; Lee HK
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267480
[TBL] [Abstract][Full Text] [Related]
19. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
20. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
